Machine learning software to design personalized neoantigen vaccines tailored to specific vaccine delivery systems

Projektinformationen

MEDIVAC

ID Finanzhilfevereinbarung: 775611

DOI 10.3030/775611

Abgeschlossenes Projekt

EK-Unterschriftsdatum 6 Mai 2017

Startdatum 1 Juni 2017

Enddatum 31 Oktober 2017

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

ONCOIMMUNITY AS
Norway

Ziel

Cancer remains a leading cause of disease and death worldwide. An estimated 14m new cancer cases were diagnosed in 2012 and 22m are predicted by 2023. Immunotherapy and particularly personalized neoantigen-based vaccines represent an exciting new weapon in the war against cancer, as they are specific to the tumor and potentially safer and more effective than other types of treatment. However, the design of neoantigen-based cancer vaccines is currently hampered by an inability to reliably select immunogenic neoantigens using the existing technologies.
OncoImmunity proposes to develop disruptive software - MEDIVAC - for the rapid and intelligent design of neoantigen-based personalized cancer vaccines, tailored to specific vaccine deliver systems (VDS). The software will leverage a machine-learning framework being developed at OncoImmunity that addresses key prediction gaps in the field of neoantigen discovery. Preliminary testing of MEDIVAC´s prediction engine reveals that it can identify immunogenic neoantigens with an unprecedented level of accuracy, and at a fraction of the time and cost of competing wet-lab methodologies. The MEDIVAC technology will enable personalized cancer vaccine companies to make safer more efficacious vaccines in an affordable and clinically actionable timeframe, and will consequently help revolutionize the treatment of cancer.
We believe the SME instrument is the ideal funding vehicle to enable OncoImmunity to overcome the remaining barriers to the market and establish the company as the leading provider of software solutions for guiding the design of cancer vaccines. Furthermore, the MEDIVAC software will help nurture and improve the competitiveness of European companies in the rapidly growing personalized cancer vaccine market, and ultimately help Europe to tackle a global cancer epidemic.

Wissenschaftliches Gebiet

• natural sciences › computer and information sciences › software
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs › vaccines
• medical and health sciences › clinical medicine › oncology
• medical and health sciences › basic medicine › immunology › immunotherapy
• natural sciences › computer and information sciences › artificial intelligence › machine learning

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.4. - Active ageing and self-management of health
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
• H2020-EU.3.1.6. - Health care provision and integrated care

Thema/Themen

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

ONCOIMMUNITY AS

• Netto-EU-Beitrag: € 50 000,00
• Adresse: ULLERNCHAUSSEEN 64 ; 0379 Oslo ; Norwegen
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Norge › Oslo og Viken › Oslo
• Region: Norge › Oslo og Viken › Oslo
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00